Clinical trials: Stage IB Pancreatic Cancer
Advanced Pancreatic Cancer
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid…
- Trial name
- NCT06821503
- Testing
- LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound)
- Where
- 16 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.
- Trial name
- NCT07640295
- Testing
- JAB-23E73 tablet，nab-paclitaxel，gemcitabine
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Pancreatic Cancer
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic…
- Trial name
- NCT07444541
- Testing
- ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Anova Innovation Limited
Triple Negative Breast Cancer, Pancreatic Carcinoma
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with…
- Conditions
- Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
- Trial name
- NCT02807844
- Testing
- MCS110, PDR001
- Where
- 20 sites in United States, Belgium and 9 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of…
- Conditions
- Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Adenocarcinoma, Lung Adenocarcinoma
- Trial name
- NCT07875920
- Testing
- Fludarabine, Cyclophosphamide, NW-301V
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Neowise Biotechnology
Pancreatic Cancer
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
This phase Ib/II study evaluates the safety and efficacy of OH2 in patients with locally advanced/metastatic pancreatic cancer who have failed first-line standard treatment.
- Trial name
- NCT04637698
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Advanced Solid Tumors, Selected Solid Tumors
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of the orally administered phosphatidylinositol 3'-kinase (PI3K) inhibitor…
- Trial name
- NCT01363232
- Testing
- BKM120 + MEK162
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 89 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Pancreatic Cancer
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
- Trial name
- NCT07806058
- Testing
- HRS-7172 + AG + SHR-1316, HRS-7172 + AG + SHR-1316;, HRS-7172 + AG;
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Neoplasms, Breast Neoplasms
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Dose escalation part: to determine the highest dose of alpelisib administered on a daily basis when given in combination with daily everolimus or in combination with daily everolimus and exemestane.
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Trial name
- NCT02077933
- Testing
- alpelisib, everolimus, exemestane
- Where
- 22 sites in United States, France and 7 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Adenocarcinoma
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
- Trial name
- NCT02231723
- Testing
- BBI608, Nab-paclitaxel, Gemcitabine
- Where
- 12 sites in United States
- Volunteers
- 139 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Pancreatic Cancer
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable patients per cohort) will…
- Trial name
- NCT01487785
- Testing
- LDE225+gemcitabine
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Trial name
- NCT06646055
- Testing
- AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Akeso
Locally Advanced or Metastatic Pancreatic Cancer With
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid…
- Trial name
- NCT07296341
- Testing
- HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine, HRS-4642;nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Cancer
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors.
- Trial name
- Cancer (NCT00955773)
- Testing
- GSK1120212 plus everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT03819387
- Testing
- NBF-006
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Nitto BioPharma, Inc.
Pancreatic Cancer
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
- Trial name
- NCT00603863
- Testing
- IMMU-107 (hPAM4)
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences